Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine
This observational study, sponsored by Korea University Guro Hospital, aims to elucidate the relationship between gut microbiota and immune response to two prominent COVID-19 vaccines: BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford/AstraZeneca). The findings could have significant implications for vaccine efficacy and personalized medicine, particularly in the context of varying immunogenicity among individuals. If successful, this research may lead to novel strategies for enhancing vaccine responses through microbiome modulation, potentially creating a new market for microbiome-targeted therapeutics in vaccine optimization. The competitive landscape includes ongoing research into microbiome interactions with other vaccines, necessitating diligence in monitoring emerging data and potential partnerships.
Indication: Microbiome
Modality: RNA therapy
Target: Gut microbiota composition as a determinant of humoral immune response to COVID-19 vaccination.
Sponsor: Korea University Guro Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Gut microbiota composition as a determinant of humoral immune response to COVID-19 vaccination.
View original source fields
Condition raw: Microbiome, Vaccine, Covid-19, SARS-CoV-2, Immunogenicity
Condition normalized: Microbiome, Vaccine, Covid-19, SARS-CoV-2, Immunogenicity
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Gut microbiota composition as a determinant of humoral immune response to COVID-19 vaccination.
Target normalized: Gut microbiota composition as a determinant of humoral immune response to COVID-19 vaccination.